For Low-Level HER2 Breast Cancer, Trastuzumab Is a No-Go

Although the study didn ' t turn out as hoped, NSABP B-47 will help inform the decision of whether patients with low-level HER2 breast cancer should receive trastuzumab.
Source: Medscape Oncology - Category: Cancer & Oncology Authors: Source Type: podcasts